Cancer gene therapy developer aims for $60M IPO; Nanowafers as an alternative to eye drops?;

> Cancer gene therapy developer MultiVir aims to raise $60 million via Nasdaq IPO that is supposed to commence during the week of May 4. More

> Contract manufacturer Recipharm agreed to produce LIDDS' phase II Liproca Depot, a reformulated candidate to treat prostate cancer via local administration. More

> Researchers at Baylor College Medicine are working on the use of drug delivering nanowafers as an alternative to eye drops. More

> New York City's Anterios--the developer of a lotion containing the active ingredient of Botox (marketed by recently acquired Allergan) that can be applied on the skin via a 10-minute massage--plans to raise $51 million via Nasdaq IPO. Earlier this month, it filed with the SEC to raise $58 million. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.